|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Horizon_Therapeutics
gptkb:Immunex
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:awarded
|
gptkb:award
|
|
gptkbp:CEO
|
gptkb:Robert_A._Bradway
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:diversityInitiatives
|
gptkb:Amgen_Foundation
|
|
gptkbp:ESRB_rating
|
gptkb:A_(MSCI,_2023)
|
|
gptkbp:focusArea
|
gptkb:cardiovascular_disease
neuroscience
oncology
biologics
biosimilars
nephrology
inflammation
bone health
|
|
gptkbp:Fortune500Rank
|
123 (2023)
|
|
gptkbp:foundedYear
|
1980
|
|
gptkbp:founder
|
gptkb:George_Rathmann
|
|
gptkbp:headquartersLocation
|
gptkb:Thousand_Oaks,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amgen Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ-100
gptkb:S&P_500
gptkb:S&P_100
|
|
gptkbp:logo
|
Amgen logo.svg
|
|
gptkbp:memberOf
|
gptkb:Biotechnology_Innovation_Organization
|
|
gptkbp:netIncome
|
$6.7 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Aimovig
gptkb:Aranesp
gptkb:Enbrel
gptkb:Epogen
gptkb:Neulasta
gptkb:Prolia
gptkb:Repatha
gptkb:Xgeva
|
|
gptkbp:numberOfEmployees
|
~25,200 (2023)
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:philanthropy
|
gptkb:Amgen_Foundation
|
|
gptkbp:researchFacilityLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
gptkb:Dublin,_Ireland
gptkb:Burnaby,_British_Columbia,_Canada
gptkb:South_San_Francisco,_California,_United_States
|
|
gptkbp:revenue
|
$28.2 billion (2023)
|
|
gptkbp:S&P500Component
|
yes
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:AMGN
|
|
gptkbp:subsidiary
|
gptkb:Immunex
gptkb:Onyx_Pharmaceuticals
gptkb:deCODE_genetics
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.amgen.com/
|
|
gptkbp:bfsParent
|
gptkb:^NDX
gptkb:Amgen_Ventures
|
|
gptkbp:bfsLayer
|
6
|